Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tharimmune, Inc. (NASDAQ: THAR) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission, including its Current Reports on Form 8-K, proxy materials, and other registration documents. These filings provide primary-source detail on Tharimmune’s clinical-stage biotechnology programs and its Canton Coin-focused digital asset treasury strategy.
Recent Form 8-K filings describe material definitive agreements such as securities purchase agreements for private placements involving common stock and pre-funded warrants, as well as an at-the-market sales agreement for common stock. They also outline the structure and intended use of proceeds from offerings designed to support both Tharimmune’s historical biotech operations and the establishment of a Canton Coin treasury and related Canton Network participation.
Other 8-Ks and proxy materials detail corporate governance and compensation matters, including amendments to the certificate of incorporation to increase authorized common stock, changes to the omnibus equity incentive plan, and the appointment of key executives such as the Chief Executive Officer, President, and Chief Financial Officer. These documents specify employment agreement terms, severance provisions, and equity award structures for senior leadership associated with the company’s biotechnology and digital asset initiatives.
Investors can also use this page to access risk factor discussions related to Tharimmune’s Canton Coin strategy, as described in its filings, including risks tied to digital asset volatility, regulatory uncertainty, and liquidity considerations. Proxy statements provide additional context on share authorization proposals and future offering authorizations under Nasdaq rules.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, capital structure changes, and leadership updates, helping readers quickly interpret complex legal and financial language. From here, you can review Tharimmune’s 8-Ks, registration statements, and proxy materials, and use the platform’s tools to track insider-related disclosures and ongoing financing arrangements as they appear in the EDGAR feed.
Tharimmune, Inc. filed a resale registration for 326,750 shares of common stock to be offered from time to time by the selling stockholder. The shares are issuable upon exercise of placement agent and series warrants tied to prior private placements in June 2024, December 2024, June 2025, and July 2025.
Tharimmune is not selling any shares in this prospectus and will not receive proceeds from the selling stockholder’s sales. The company would receive cash only if the warrants are exercised for cash. The filing states beneficial ownership limits of 4.99% or 9.99%, as applicable, on exercises. The stock trades on Nasdaq as “THAR”; the last reported sale price was $3.16 per share on October 15, 2025. As of October 15, 2025, shares outstanding were 7,608,939.
Tharimmune is a clinical-stage biotech advancing TH104 and other immunology and IO programs, and qualifies as an emerging growth company and smaller reporting company.
Tharimmune, Inc. filed a Form S-8 registering 1,207,398 additional shares of common stock for issuance under its Amended and Restated 2023 Omnibus Equity Incentive Plan.
The filing relies on General Instruction E to add to previously registered plan shares and incorporates prior S-8s by reference, while updating Items 3 and 8. It outlines standard Delaware DGCL-based indemnification, notes existing indemnification agreements and D&O insurance, and includes exhibits such as the legal opinion, auditor consent, and the filing fee table.
Tharimmune, Inc. (THAR) filed a Form 8-K disclosing a corporate governance update. The filing includes a Certificate of Amendment to the Certificate of Incorporation, dated October 10, 2025, furnished as Exhibit 3.1.
The excerpt does not specify the substance of the amendment, and there are no financial results, transactions, or guidance changes disclosed here. The document is signed by Chief Executive Officer Sireesh Appajosyula. Without the amendment’s details, potential effects on shareholders—such as changes to share structure or corporate provisions—are not determinable from this text.
Tharimmune, Inc. reported that stockholders approved several key proposals at a special meeting on October 9, 2025. Investors authorized the board to amend the certificate of incorporation to increase the total number of common shares the company is allowed to issue from 250,000,000 to a range between 500,000,000 and 1,000,000,000, with the exact level and timing left to the board’s discretion any time before October 9, 2026.
Stockholders also approved an amendment to the Amended and Restated 2023 Omnibus Equity Incentive Plan, raising the pool of common shares reserved for equity awards to 2,000,000 shares from 792,602 shares. In addition, they approved a proposal allowing the company to issue securities in one or more non-public offerings consistent with Nasdaq Marketplace Rules 5635(a) and 5635(d), giving the company flexibility to raise capital through private transactions if it chooses.
Tharimmune, Inc. entered into a new agreement that changes how certain existing warrants work. On October 1, 2025, the company amended warrants held by investors that are exercisable for an aggregate 3,408,110 shares of common stock. The amendment makes these warrants immediately exercisable, meaning holders can now convert them into common shares without waiting for any future vesting or timing conditions.
This change does not create new warrants, but updates the terms on existing ones. The eventual impact will depend on how many warrant holders choose to exercise and convert their rights into common stock.
TharImmune, Inc. discloses beneficial ownership for named executives, directors and major shareholders. Chairman Vincent LoPriore holds 1,121,770 shares (18.45%). All named executive officers and directors as a group hold 1,550,334 shares (25.61%). Institutional and large holders listed include Gravitas Capital LP: 1,071,770 shares (17.77%), Evelyn Rickel Trust FBO Kenneth D. Rickel: 885,644 shares (14.32%), and David Clarke: 783,842 shares (12.79%). Several other holders report positions between about 5% and 8%, and certain individual directors report smaller, de minimis stakes. The table reflects ownership percentages and share counts without forward-looking commentary.
Tharimmune, Inc. preliminary proxy excerpts show ownership stakes for directors, named executive officers and major shareholders. Vincent LoPriore is listed with 1,121,770 shares (18.45%). All named executive officers and directors as a group (7 persons) hold 1,550,334 shares (25.61%). Institutional or large holders shown include Gravitas Capital LP 1,071,770 shares (17.77%), Evelyn Rickel Trust FBO Kenneth D. Rickel 885,644 shares (14.32%), David Clarke 783,842 shares (12.79%), SDS Capital Partners II, LLC 485,890 shares (8.00%), GSB Holdings, Inc. 418,799 shares (6.99%), and Brightforge Management, LLC 310,910 shares (5.25%). The extract appears to be a partial table of beneficial ownership and signature lines from the preliminary proxy.
Tharimmune, Inc. reported that it has regained compliance with Nasdaq listing requirements related to stockholders’ equity. On September 5, 2025, the company received a letter from Nasdaq confirming that, based on a filing showing stockholders’ equity of $6,876,335 as of August 31, 2025, it meets Nasdaq Listing Rule 5550(b)(1). Nasdaq stated that the compliance matter is now closed, meaning Tharimmune’s common stock continues to qualify for listing on The Nasdaq Stock Market.
Tharimmune, Inc. filed Amendment No. 1 to its Form S-3 registration statement, focused on updating back-end disclosure items rather than changing the preliminary prospectus. The amendment revises Item 16 and adds or updates certain exhibits, including legal opinions, consents and previously filed corporate and transaction documents. It also details estimated offering-related expenses, with total fees and costs of $90,819.88, including SEC registration, legal, accounting, printing and miscellaneous expenses, which are to be borne by the selling stockholders (other than underwriting discounts and commissions). The filing restates the company’s indemnification provisions for directors and officers under Delaware law and confirms standard Securities Act undertakings and signature authorizations.
FAQ
What is the current stock price of Tharimmune (THAR)?
What is the market cap of Tharimmune (THAR)?
